Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29703778

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2018 Jul 5
First author
LaCasce AS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2018 Jul 5;132(1):1-3. doi: 10.1182/blood-2018-05-848366.
    note
    Source null
    related pmid
    29976776
    relationship
    Comment in

Authors and identifiers

  1. name
    LaCasce AS
    type
    Author
  2. name
    Bociek RG
    type
    Author
  3. name
    Sawas A
    type
    Author
  4. name
    Caimi P
    type
    Author
  5. name
    Agura E
    type
    Author
  6. name
    Matous J
    type
    Author
  7. name
    Ansell SM
    type
    Author
  8. name
    Crosswell HE
    type
    Author
  9. name
    Islas-Ohlmayer M
    type
    Author
  10. name
    Behler C
    type
    Author
  11. name
    Cheung E
    type
    Author
  12. name
    Forero-Torres A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    LaCasce AS
    type
    Author
  2. name
    Bociek RG
    type
    Author
  3. name
    Sawas A
    type
    Author
  4. name
    Caimi P
    type
    Author
  5. name
    Agura E
    type
    Author
  6. name
    Matous J
    type
    Author
  7. name
    Ansell SM
    type
    Author
  8. name
    Crosswell HE
    type
    Author
  9. name
    Islas-Ohlmayer M
    type
    Author
  10. name
    Behler C
    type
    Author
  11. name
    Cheung E
    type
    Author
  12. name
    Forero-Torres A
    type
    Author
bibliography ids
  1. nci-bib-e398e2ac0d060d6020298201
book metadata
content sha256
eb4668c933db2f89dc1ffbe84760440f6d932791e4672aac6aa16de60003bcb6
document type
citation
dois
  1. 10.1182/blood-2017-11-815183
electronic publication date
display
2018 Apr 27
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29703778
immutable id
pubmed:29703778@eb4668c933db2f89dc1ffbe84760440f6d932791e4672aac6aa16de60003bcb6
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
1
name
Blood
nlm unique id
7603509
pages
40-48
volume
132
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2018 Jul 5;132(1):1-3. doi: 10.1182/blood-2018-05-848366.
    note
    Source null
    related pmid
    29976776
    relationship
    Comment in
outcomes validated
false
pmid
29703778
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
6196b7d15d57a9560682a5760b8d57c8fe1976b9af521969577740750aeb9290
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Jul 5
precision
day
year
2018
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
  4. Multicenter Study
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29703778/
title
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Preserved source evidence · Not medical advice